Drugs / Aminophylline

Regulatory milestones approvals, filings & regulatory actions · 1 recorded

MilestoneJurisdictionBrandIndicationDateSentence it was read from
Approved US (FDA) AMINOPHYLLIN 1940-04-19 fda.gov

Trials 20 · a red edge is where a trial was stopped

19381939194019411942194319441945194619471948194919501951195219531954195519561957195819591960196119621963196419651966196719681969197019711972197319741975197619771978197919801981198219831984198519861987198819891990199119921993199419951996199719981999200020012002200320042005200620072008200920102011201220132014201520162017201820192020202120222023202420252026202720282029
PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 01 trial
Phase 0 NCT01240824 Jul 2010 → Feb 2011 urinary bladder cancer University of Virginia Completed No outcome recorded
Phase 11 trial
Phase 1 NCT01794078 Sep 2013 → Sep 2014 acute mountain sickness Robert J Noveck, M.D. Completed No outcome recorded
Phase 24 trials
Phase 2 NCT07617896 May 2026 → Apr 2027 expected ureterolithiasis, urolithiasis Beni-Suef University Recruiting No outcome recorded
Phase 2 NCT07623876 May 2026 → Apr 2027 expected urolithiasis Beni-Suef University Recruiting No outcome recorded
Phase 2 NCT07617948 Apr 2026 → Mar 2027 expected acute kidney injury, anuria, ureterolithiasis, urinary tract obstruction Beni-Suef University Recruiting No outcome recorded
Phase 2 NCT00312273 Jan 2001 → Jul 2004 cardiac arrest Vancouver General Hospital Completed No outcome recorded
Phase 2/31 trial
Phase 2/3 NCT06196853 Dec 2025 → Sep 2026 expected acute kidney injury, renal tubule disorder Mahidol University Not yet recruiting No outcome recorded
Phase 31 trial
Phase 3 NCT02522013 Oct 2015 → Oct 2016 intracranial hypotension The First Affiliated Hospital of Zhengzhou University Completed No outcome recorded
Phase 46 trials
Phase 4 NCT05666219 Dec 2022 → Dec 2023 heart conduction disease, inferior myocardial infarction National Institute of Cardiovascular Diseases, Pakistan Withdrawn No outcome recorded
Phase 4 NCT04101500 Apr 2019 → Dec 2020 chronic obstructive pulmonary disease Union Hospital, Tongji Medical College, Huazhong University of Science and Technology Unknown No outcome recorded
Phase 4 NCT01655524 Jul 2012 → Jul 2014 coronary artery disorder Rush University Medical Center Withdrawn No outcome recorded
Phase 4 NCT01336140 Jun 2011 → May 2012 Rush University Medical Center Completed No outcome recorded
Phase 4 NCT01250496 Nov 2010 → Nov 2011 Rush University Medical Center Terminated No outcome recorded
Phase 4 NCT01594489 Jan 2009 → Sep 2012 acute kidney injury Ospedale Misericordia e Dolce Completed No outcome recorded
Phase not applicable6 trials
NCT06830577 Mar 2025 → Jan 2026 overdue ureteral disorder, urolithiasis Ain Shams University Recruiting No outcome recorded
NCT06125665 Nov 2023 → Apr 2024 chronic obstructive pulmonary disease, morbid obesity Tanta University Unknown No outcome recorded
NCT05738135 Feb → Aug 2023 Tanta University Completed No outcome recorded
NCT05705050 Feb → Jun 2023 Tanta University Completed No outcome recorded
NCT01759862 Nov 2012 → Jan 2017 Stanford University Completed No outcome recorded
NCT01280071 Tel-Aviv Sourasky Medical Center Unknown No outcome recorded
Also used as a comparator or background therapy in 20 trials
PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 01 trial
Phase 0 NCT02983422 Comparator Dec 2016 → Jun 2017 acute kidney injury Shanghai Jiao Tong University Affiliated Sixth People's Hospital Unknown No outcome recorded
Phase 14 trials
Phase 1 NCT04151381 Comparator Nov → Dec 2019 Beni-Suef University Unknown No outcome recorded
Phase 1 NCT03152942 Comparator Oct 2017 → Oct 2018 obstetric disorder St Stephens Aids Trust Unknown No outcome recorded
Phase 1 NCT01530464 Comparator Feb → Apr 2012 pulmonary hypertension Thies Schroeder Completed No outcome recorded
Phase 1 NCT01587027 Comparator Dec 2011 → Feb 2012 altitude sickness Poudre Valley Health System Completed No outcome recorded
Phase 1/21 trial
Phase 1/2 NCT01702025 Comparator Jun → Dec 2012 Colorado State University Completed No outcome recorded
Phase 22 trials
Phase 2 NCT07528118 Background Aug 2023 → Jun 2024 Sargodha Medical College Completed No outcome recorded
Phase 2 NCT01022151 Comparator Nov 2007 → Jul 2010 King Faisal University Completed No outcome recorded
Phase 2/31 trial
Phase 2/3 NCT05933642 Comparator Jul → Dec 2023 acute kidney injury University of Malaya Unknown No outcome recorded
Phase 33 trials
Phase 3 NCT07011134 Comparator Jun → Aug 2025 Hany Mohammed El-Hadi Shoukat Mohammed Completed No outcome recorded
Phase 3 NCT03897335 Comparator Feb 2019 → Feb 2023 acute kidney injury Le Bonheur Children's Hospital Unknown No outcome recorded
Phase 3 NCT00442338 Comparator Mar → Aug 2007 asthma Organon and Co Completed No outcome recorded
Phase 43 trials
Phase 4 NCT05655806 Comparator Dec 2022 → Jun 2023 Cairo University Unknown No outcome recorded
Phase 4 NCT05552404 Comparator Oct → Dec 2022 Ain Shams University Completed No outcome recorded
Phase 4 NCT03997006 Comparator Jan 2019 → Jan 2020 intracranial hypotension Damanhour Teaching Hospital Completed No outcome recorded
Phase not applicable5 trials
NCT07348510 Comparator Jan → Jul 2026 overdue Cairo University Recruiting No outcome recorded
NCT04274413 Background Feb 2021 CFTR-related disorder, cystic fibrosis The Hospital for Sick Children Withdrawn No outcome recorded
NCT03296579 Comparator Jun → Nov 2018 acute asthma, childhood onset asthma University of British Columbia Unknown No outcome recorded
NCT02310789 Background Jul 2015 → Aug 2016 cystic fibrosis Richard Barry Moss Completed No outcome recorded
NCT01245595 Comparator Nov 2010 → May 2014 acute kidney injury Stanford University Completed No outcome recorded

Evidence & citations 5 cited values

Every value below carries the sentence it was read from. 41 sources stand behind the page.

FieldValueCited text
Known as Aminophylline “Lastly, beta-adrenergic sweating will be stimulated by injecting a combination of the following drugs: atropine, isoproterenol, and aminophylline (β-cocktail).” NCT04274413
39

“Cocktail composed of atropine (280µM), isoproterenol (160µM), and aminophylline (20 mM).” NCT02310789

AminophyllineNCT01655524

NCT01530464

NCT04151381

NCT06125665

NCT05655806

NCT06196853

NCT05738135

NCT06830577

NCT01759862

NCT03997006

NCT03152942

NCT05552404

NCT01280071

NCT07623876

NCT07348510

NCT03897335

NCT07528118

NCT01587027

NCT07617948

NCT07617896

NCT03296579

NCT05666219

NCT07011134

NCT05705050

NCT02983422

NCT01245595

NCT01702025

NCT02522013

NCT01240824

NCT05933642

NCT04101500

NCT01794078

NCT00312273

NCT01022151

NCT01336140

NCT00442338

NCT01250496

NCT01594489

Known as aminophylline hydrate “Drug: aminophylline hydrateNCT00442338
Action Inhibit “Aminophylline is a competitive antagonist of adenosine.” NCT00312273
Modality Small molecule “Aminophylline, a methylxanthine derivative” NCT06830577
Route Intravenous “receive intravenous aminophylline (250 mg, and an additional 250 mg if necessary)” PMID 16698410 May 2006